### High-Level Plan

1. **Draft Initial Review Sections**: Create drafts for the "Summary," "Strengths," "Weaknesses," and "Questions" sections based on the initial feedback from the co-workers and the paper content.

2. **Integrate Detailed Feedback**: Incorporate detailed feedback from the co-workers into the respective sections of the review. Ensure that the feedback is integrated coherently and logically.

3. **Refine and Finalize Review**: Review the integrated feedback and make necessary refinements to ensure clarity, coherence, and completeness. Finalize the review by ensuring it adheres to the specified Markdown headers and structure.

4. **Assign Overall Rating**: Based on the strengths, weaknesses, and the overall quality of the paper, assign an overall rating using the provided rubric (1-3: reject, 4-5: borderline, 6-7: weak accept, 8-10: accept).

5. **Final Review Submission**: Submit the final review, ensuring it includes all necessary sections and the overall rating.

### Current Step: Draft Initial Review Sections

#### ## Summary

The paper titled "IgSeek: Fast and Accurate Antibody Design via Structure Retrieval" introduces a novel structure-retrieval framework for inferring Complementarity-Determining Region (CDR) sequences in antibodies. The method leverages a multi-channel equivariant graph neural network (MEGNN) to generate geometric representations of CDR backbone structures and retrieves structurally similar CDRs from a natural antibody database. The paper demonstrates that IgSeek outperforms state-of-the-art methods in both sequence recovery and inference speed, offering a new retrieval-based perspective for therapeutic protein design.

#### ## Strengths

- **Novel Approach**: The retrieval-based framework is a significant departure from traditional inverse folding methods, addressing the issue of hallucinations in sequence design.
- **High Performance**: IgSeek achieves superior performance in sequence recovery and inference speed compared to state-of-the-art methods.
- **Generalization**: The method generalizes well to T-Cell Receptors (TCRs) without additional training, indicating its robustness and broad applicability.
- **Efficiency**: The model is highly efficient, achieving at least a 20x speed-up in inference time, which is crucial for high-throughput design.
- **Comprehensive Evaluation**: The paper includes a thorough evaluation of the model's performance across multiple datasets and competitors, using metrics such as AUROC and AAR.

#### ## Weaknesses

- **Lack of Statistical Significance**: The paper does not explicitly mention the use of statistical tests to validate the performance improvements claimed by IgSeek over the baseline methods.
- **Database Dependency**: The method relies heavily on the availability and diversity of a large CDR database. If the database lacks certain structural motifs, the method may fail to retrieve suitable templates.
- **Limited Ablation Studies**: The paper lacks detailed ablation studies to isolate the contributions of different components of the IgSeek framework.
- **Real-World Impact**: While the paper discusses the potential real-world impact, it could benefit from additional experiments, such as wet-lab validation, to demonstrate the functional efficacy of the designed antibodies.

#### ## Questions

- **Statistical Validation**: Were any statistical tests conducted to validate the performance improvements claimed by IgSeek over the baseline methods?
- **Database Maintenance**: How is the CDR vector database maintained and updated as new structures are added? What strategies are in place to handle out-of-distribution structures?
- **Sensitivity Analysis**: Is there a sensitivity analysis on the choice of K in K-NN retrieval? What is the trade-off between K and performance?
- **Broader Applicability**: Can the retrieval-based approach be extended to full antibody design or antigen-specific binder design, where the framework and CDRs are co-designed?
- **Functional Validation**: Are there plans to include wet-lab validation experiments to demonstrate the functional efficacy of the designed antibodies?

### Current Step: Integrate Detailed Feedback

#### ## Summary

The paper titled "IgSeek: Fast and Accurate Antibody Design via Structure Retrieval" introduces a novel structure-retrieval framework for inferring Complementarity-Determining Region (CDR) sequences in antibodies. The method leverages a multi-channel equivariant graph neural network (MEGNN) to generate geometric representations of CDR backbone structures and retrieves structurally similar CDRs from a natural antibody database. The paper demonstrates that IgSeek outperforms state-of-the-art methods in both sequence recovery and inference speed, offering a new retrieval-based perspective for therapeutic protein design.

#### ## Strengths

- **Novel Approach**: The retrieval-based framework is a significant departure from traditional inverse folding methods, addressing the issue of hallucinations in sequence design. The use of MEGNN for encoding CDR structures is innovative and well-justified.
- **High Performance**: IgSeek achieves superior performance in sequence recovery and inference speed compared to state-of-the-art methods. The model outperforms FoldSeek in structure retrieval and is 2.6x faster. It also outperforms ProteinMPNN, ESM-IF1, AbMPNN, and AntiFold in sequence recovery, particularly for hyper-variable CDR loops like CDR-H3.
- **Generalization**: The method generalizes well to T-Cell Receptors (TCRs) without additional training, indicating its robustness and broad applicability. The visualization analysis using T-SNE supports the model's ability to capture meaningful structural representations.
- **Efficiency**: The model is highly efficient, achieving at least a 20x speed-up in inference time, which is crucial for high-throughput design. The paper also explains the performance degradation of AntiFold and AbMPNN in their setup, highlighting the limitations of existing methods when only CDR structure is provided.
- **Comprehensive Evaluation**: The paper includes a thorough evaluation of the model's performance across multiple datasets and competitors, using metrics such as AUROC and AAR. The experimental setup, including the datasets and competitors, is well-documented, allowing for easy replication of the experiments.

#### ## Weaknesses

- **Lack of Statistical Significance**: The paper does not explicitly mention the use of statistical tests to validate the performance improvements claimed by IgSeek over the baseline methods. Including statistical tests (e.g., t-tests, Wilcoxon signed-rank tests) would provide stronger evidence for the significance of the results.
- **Database Dependency**: The method relies heavily on the availability and diversity of a large CDR database. If the database lacks certain structural motifs, the method may fail to retrieve suitable templates. The paper should discuss this limitation and perhaps propose strategies for handling out-of-distribution structures.
- **Limited Ablation Studies**: The paper lacks detailed ablation studies to isolate the contributions of different components of the IgSeek framework. Including these studies would provide a deeper understanding of the contributions of different components.
- **Real-World Impact**: While the paper discusses the potential real-world impact, it could benefit from additional experiments, such as wet-lab validation, to demonstrate the functional efficacy of the designed antibodies. The paper should also discuss the real-world impact of the results, particularly in the context of therapeutic antibody design.
- **Implementation Details**: While the paper describes the overall architecture and training process, it would be beneficial to include more implementation details, such as the specific architecture of the MLP layers, the learning rate schedule, and the optimization algorithm used. The paper does not mention whether the code and data used for the experiments will be made publicly available, which would significantly enhance reproducibility.

#### ## Questions

- **Statistical Validation**: Were any statistical tests conducted to validate the performance improvements claimed by IgSeek over the baseline methods? Including statistical tests would provide stronger evidence for the significance of the results.
- **Database Maintenance**: How is the CDR vector database maintained and updated as new structures are added? What strategies are in place to handle out-of-distribution structures? The paper should clarify how the CDR vector database is maintained and updated as new structures are added.
- **Sensitivity Analysis**: Is there a sensitivity analysis on the choice of K in K-NN retrieval? What is the trade-off between K and performance? The paper should discuss the choice of K=10 for nearest neighbors and provide a sensitivity analysis.
- **Broader Applicability**: Can the retrieval-based approach be extended to full antibody design or antigen-specific binder design, where the framework and CDRs are co-designed? The paper should explore whether the retrieval-based approach can be extended to full antibody or antigen-specific design.
- **Functional Validation**: Are there plans to include wet-lab validation experiments to demonstrate the functional efficacy of the designed antibodies? Including wet-lab validation experiments would provide stronger evidence for the real-world impact of the results.
- **Theoretical Justification**: The paper should clarify the definition of "isomorphic structure retrieval" and how it is distinguished from other retrieval methods. The theoretical justification for the E(3) equivariance of MEGNN is well-justified and theoretically sound, which is a strong point in favor of the model's robustness.

### Current Step: Refine and Finalize Review

#### ## Summary

The paper titled "IgSeek: Fast and Accurate Antibody Design via Structure Retrieval" introduces a novel structure-retrieval framework for inferring Complementarity-Determining Region (CDR) sequences in antibodies. The method leverages a multi-channel equivariant graph neural network (MEGNN) to generate geometric representations of CDR backbone structures and retrieves structurally similar CDRs from a natural antibody database. The paper demonstrates that IgSeek outperforms state-of-the-art methods in both sequence recovery and inference speed, offering a new retrieval-based perspective for therapeutic protein design.

#### ## Strengths

- **Novel Approach**: The retrieval-based framework is a significant departure from traditional inverse folding methods, addressing the issue of hallucinations in sequence design. The use of MEGNN for encoding CDR structures is innovative and well-justified.
- **High Performance**: IgSeek achieves superior performance in sequence recovery and inference speed compared to state-of-the-art methods. The model outperforms FoldSeek in structure retrieval and is 2.6x faster. It also outperforms ProteinMPNN, ESM-IF1, AbMPNN, and AntiFold in sequence recovery, particularly for hyper-variable CDR loops like CDR-H3.
- **Generalization**: The method generalizes well to T-Cell Receptors (TCRs) without additional training, indicating its robustness and broad applicability. The visualization analysis using T-SNE supports the model's ability to capture meaningful structural representations.
- **Efficiency**: The model is highly efficient, achieving at least a 20x speed-up in inference time, which is crucial for high-throughput design. The paper also explains the performance degradation of AntiFold and AbMPNN in their setup, highlighting the limitations of existing methods when only CDR structure is provided.
- **Comprehensive Evaluation**: The paper includes a thorough evaluation of the model's performance across multiple datasets and competitors, using metrics such as AUROC and AAR. The experimental setup, including the datasets and competitors, is well-documented, allowing for easy replication of the experiments.

#### ## Weaknesses

- **Lack of Statistical Significance**: The paper does not explicitly mention the use of statistical tests to validate the performance improvements claimed by IgSeek over the baseline methods. Including statistical tests (e.g., t-tests, Wilcoxon signed-rank tests) would provide stronger evidence for the significance of the results.
- **Database Dependency**: The method relies heavily on the availability and diversity of a large CDR database. If the database lacks certain structural motifs, the method may fail to retrieve suitable templates. The paper should discuss this limitation and perhaps propose strategies for handling out-of-distribution structures.
- **Limited Ablation Studies**: The paper lacks detailed ablation studies to isolate the contributions of different components of the IgSeek framework. Including these studies would provide a deeper understanding of the contributions of different components.
- **Real-World Impact**: While the paper discusses the potential real-world impact, it could benefit from additional experiments, such as wet-lab validation, to demonstrate the functional efficacy of the designed antibodies. The paper should also discuss the real-world impact of the results, particularly in the context of therapeutic antibody design.
- **Implementation Details**: While the paper describes the overall architecture and training process, it would be beneficial to include more implementation details, such as the specific architecture of the MLP layers, the learning rate schedule, and the optimization algorithm used. The paper does not mention whether the code and data used for the experiments will be made publicly available, which would significantly enhance reproducibility.

#### ## Questions

- **Statistical Validation**: Were any statistical tests conducted to validate the performance improvements claimed by IgSeek over the baseline methods? Including statistical tests would provide stronger evidence for the significance of the results.
- **Database Maintenance**: How is the CDR vector database maintained and updated as new structures are added? What strategies are in place to handle out-of-distribution structures? The paper should clarify how the CDR vector database is maintained and updated as new structures are added.
- **Sensitivity Analysis**: Is there a sensitivity analysis on the choice of K in K-NN retrieval? What is the trade-off between K and performance? The paper should discuss the choice of K=10 for nearest neighbors and provide a sensitivity analysis.
- **Broader Applicability**: Can the retrieval-based approach be extended to full antibody design or antigen-specific binder design, where the framework and CDRs are co-designed? The paper should explore whether the retrieval-based approach can be extended to full antibody or antigen-specific design.
- **Functional Validation**: Are there plans to include wet-lab validation experiments to demonstrate the functional efficacy of the designed antibodies? Including wet-lab validation experiments would provide stronger evidence for the real-world impact of the results.
- **Theoretical Justification**: The paper should clarify the definition of "isomorphic structure retrieval" and how it is distinguished from other retrieval methods. The theoretical justification for the E(3) equivariance of MEGNN is well-justified and theoretically sound, which is a strong point in favor of the model's robustness.

### Current Step: Assign Overall Rating

Based on the strengths, weaknesses, and the overall quality of the paper, I assign an overall rating of **8**. The paper presents a novel and significant contribution to the field of antibody design, with strong experimental results and a well-justified methodology. However, there are areas for improvement, particularly in terms of statistical validation, database maintenance, and real-world impact, which could be addressed in future work.

### Current Step: Final Review Submission

## Summary

The paper titled "IgSeek: Fast and Accurate Antibody Design via Structure Retrieval" introduces a novel structure-retrieval framework for inferring Complementarity-Determining Region (CDR) sequences in antibodies. The method leverages a multi-channel equivariant graph neural network (MEGNN) to generate geometric representations of CDR backbone structures and retrieves structurally similar CDRs from a natural antibody database. The paper demonstrates that IgSeek outperforms state-of-the-art methods in both sequence recovery and inference speed, offering a new retrieval-based perspective for therapeutic protein design.

## Strengths

- **Novel Approach**: The retrieval-based framework is a significant departure from traditional inverse folding methods, addressing the issue of hallucinations in sequence design. The use of MEGNN for encoding CDR structures is innovative and well-justified.
- **High Performance**: IgSeek achieves superior performance in sequence recovery and inference speed compared to state-of-the-art methods. The model outperforms FoldSeek in structure retrieval and is 2.6x faster. It also outperforms ProteinMPNN, ESM-IF1, AbMPNN, and AntiFold in sequence recovery, particularly for hyper-variable CDR loops like CDR-H3.
- **Generalization**: The method generalizes well to T-Cell Receptors (TCRs) without additional training, indicating its robustness and broad applicability. The visualization analysis using T-SNE supports the model's ability to capture meaningful structural representations.
- **Efficiency**: The model is highly efficient, achieving at least a 20x speed-up in inference time, which is crucial for high-throughput design. The paper also explains the performance degradation of AntiFold and AbMPNN in their setup, highlighting the limitations of existing methods when only CDR structure is provided.
- **Comprehensive Evaluation**: The paper includes a thorough evaluation of the model's performance across multiple datasets and competitors, using metrics such as AUROC and AAR. The experimental setup, including the datasets and competitors, is well-documented, allowing for easy replication of the experiments.

## Weaknesses

- **Lack of Statistical Significance**: The paper does not explicitly mention the use of statistical tests to validate the performance improvements claimed by IgSeek over the baseline methods. Including statistical tests (e.g., t-tests, Wilcoxon signed-rank tests) would provide stronger evidence for the significance of the results.
- **Database Dependency**: The method relies heavily on the availability and diversity of a large CDR database. If the database lacks certain structural motifs, the method may fail to retrieve suitable templates. The paper should discuss this limitation and perhaps propose strategies for handling out-of-distribution structures.
- **Limited Ablation Studies**: The paper lacks detailed ablation studies to isolate the contributions of different components of the IgSeek framework. Including these studies would provide a deeper understanding of the contributions of different components.
- **Real-World Impact**: While the paper discusses the potential real-world impact, it could benefit from additional experiments, such as wet-lab validation, to demonstrate the functional efficacy of the designed antibodies. The paper should also discuss the real-world impact of the results, particularly in the context of therapeutic antibody design.
- **Implementation Details**: While the paper describes the overall architecture and training process, it would be beneficial to include more implementation details, such as the specific architecture of the MLP layers, the learning rate schedule, and the optimization algorithm used. The paper does not mention whether the code and data used for the experiments will be made publicly available, which would significantly enhance reproducibility.

## Questions

- **Statistical Validation**: Were any statistical tests conducted to validate the performance improvements claimed by IgSeek over the baseline methods? Including statistical tests would provide stronger evidence for the significance of the results.
- **Database Maintenance**: How is the CDR vector database maintained and updated as new structures are added? What strategies are in place to handle out-of-distribution structures? The paper should clarify how the CDR vector database is maintained and updated as new structures are added.
- **Sensitivity Analysis**: Is there a sensitivity analysis on the choice of K in K-NN retrieval? What is the trade-off between K and performance? The paper should discuss the choice of K=10 for nearest neighbors and provide a sensitivity analysis.
- **Broader Applicability**: Can the retrieval-based approach be extended to full antibody design or antigen-specific binder design, where the framework and CDRs are co-designed? The paper should explore whether the retrieval-based approach can be extended to full antibody or antigen-specific design.
- **Functional Validation**: Are there plans to include wet-lab validation experiments to demonstrate the functional efficacy of the designed antibodies? Including wet-lab validation experiments would provide stronger evidence for the real-world impact of the results.
- **Theoretical Justification**: The paper should clarify the definition of "isomorphic structure retrieval" and how it is distinguished from other retrieval methods. The theoretical justification for the E(3) equivariance of MEGNN is well-justified and theoretically sound, which is a strong point in favor of the model's robustness.

RATING: 8